Elizabeth M. Topp

Adhesive/Dentin Interface: The Weak Link in the Composite Restoration

Results from clinical studies suggest that more than half of the 166 million dental restorations that were placed in the United States in 2005 were replacements for failed restorations. This emphasis on replacement therapy is expected to grow as dentists use composite as opposed to dental amalgam to restore moderate to large posterior lesions. Composite restorations have higher failure rates, more recurrent caries, and increased frequency of replacement as compared to amalgam. Penetration of bacterial enzymes, oral fluids, and bacteria into the crevices between the tooth and composite undermines the restoration and leads to recurrent decay and premature failure. Under in vivo conditions the bond formed at the adhesive/dentin interface can be the first defense against these noxious, damaging substances. The intent of this article is to review structural aspects of the clinical substrate that impact bond formation at the adhesive/dentin interface; to examine physico-chemical factors that affect the integrity and durability of the adhesive/dentin interfacial bond; and to explore how these factors act synergistically with mechanical forces to undermine the composite restoration. The article will examine the various avenues that have been pursued to address these problems and it will explore how alterations in material chemistry could address the detrimental impact of physico-chemical stresses on the bond formed at the adhesive/dentin interface.

Effect of formulation variables on drug and polymer release from HPMC-based matrix tablets

Abstract The objective of this work was to assess the effect of two formulation variables, hydroxypropylmethylcellulose (HPMC)/lactose ratio and HPMC viscosity grade, on the release of a model drug and HPMC, as well as the mechanism of drug release from HPMC-based matrix tablets. A water-soluble compound, adinazolam mesylate, was used as the model drug. Both drug and HPMC release were found to be a function of the formulation variables, with higher drug and HPMC release rates for formulations with lower HPMC/lactose ratios and lower HPMC viscosity grades. However, the K15M and K100M formulations had identical drug release profiles. All the drug release data fit well to the Higuchi expression. By comparing the drug and HPMC release data, it was concluded that diffusion of drug through the hydrated gel layer was the predominant drug release mechanism for most of the formulations studied.

Gellan-based systems for ophthalmic sustained delivery of methylprednisolone

Abstract Gellan is an anionic exocellular polysaccharide of microbial origin, having a characteristic property of cation-induced gellation. In the current study, gellan was evaluated for applications in ocular sustained release devices. A methylprednisolone (MP) ester of gellan (gellan-MP) was synthesized. Sustained release dosage forms evaluated were gellan-MP films, gellan films with physically incorporated MP and eye drops of MP suspended in a 0.6% w/w/ gellan dispersion in water. The control dosage form was a suspension of MP in normal saline. In vitro release ofMP from the test dosage forms was determined in a pH 7.4 phosphate buffer at 32 °C using a rotating bottle apparatus. MP concentrations in the tear fluid of New Zealand white rabbits were measured after ocular application of the dosage forms. In vitro, the gellan-MP films released covalently bound MP in an approximate zero-order pattern, whereas the release of physically incorporated MP from the gellan eye drops and films followed a square root of time relationship and anomalous kinetics, respectively. Compared with the MP suspension control, the gellan-MP films yielded an approximately 4-fold higher area under tear fluid concentration vs time curve, AUC0–8h, but exhibited a tendency to slip out of the eye due to a high degree of swelling. The in vivo release from films containing physically incorporated MP showed higher variability and provided mean AUC0–8h values approximately equal to the control values. The gellan eye drops containing MP yielded 2.6-fold higher AUC0–8h values than the control and also provided ease of administration. Gellan solutions might thus provide a versatile vehicle for ocular sustained release of drugs. The results also show that the gellan-MP ester can be used to increase the residence time of methylprednisolone in the tear fluid of rabbits.

Application of benzyl hyaluronate membranes as potential wound dressings: evaluation of water vapour and gas permeabilities

Membranes of 75% and 100% benzyl hyaluronate esters (percentage of total carboxylate groups esterified) were prepared and their water vapour, oxygen and carbon dioxide transmission rates determined. The values of these properties were compared with the values obtained for several commercial wound dressings under the same conditions. The benzyl hyaluronate membranes showed water vapour transmission rates (2157-2327 gm-2 per day) comparable to those from commercial skin dressings (426-2047 gm-2 per day). In the dry state, the benzyl hyaluronate membranes showed lower oxygen and carbon dioxide transmission rates. Taking into account the biocompatibility of the hyaluronic acid esters, and the possibility that therapeutic agents could be incorporated into these membranes, the results indicate that the benzyl hyaluronate membranes have potential wound dressing applications.

Microspheres of hyaluronic acid esters—Fabrication methods and in vitro hydrocortisone release

Abstract Microspheres 10 to 100 μm in diameter have been prepared from various esters of hyaluronic acid using a solvent evaporation method. A model compound, hydrocortisone, has been incorporated into these microspheres. The drug can be either physically dispersed in the polymer matrix, or chemically bound to the polymer backbone through an ester linkage. When the drug was physically dispersed, its release into a well-stirred buffer solution was essentially complete in 10 minutes. When the drug was covalently bound to the polymer, the release was much slower, requiring more than 100 hours in some cases. The release rate of covalently bound drug was found to be constant (zero order) over most of the release period. The release of covalently bound drug is thought to be controlled primarily by the hydrolysis of the ester bond.

Immunogenicity of Therapeutic Protein Aggregates

Therapeutic proteins have a propensity for aggregation during manufacturing, shipping, and storage. The presence of aggregates in protein drug products can induce adverse immune responses in patients that may affect safety and efficacy, and so it is of concern to both manufacturers and regulatory agencies. In this vein, there is a lack of understanding of the physicochemical determinants of immunological responses and a lack of standardized analytical methods to survey the molecular properties of aggregates associated with immune activation. In this review, we provide an overview of the basic immune mechanisms in the context of interactions with protein aggregates. We then critically examine the literature with emphasis on the underlying immune mechanisms as they relate to aggregate properties. Finally, we highlight the gaps in our current understanding of this issue and offer recommendations for future research.

In vitro Performance of Nano-heterogeneous Dentin Adhesive

Water is ubiquitous in the mouths of healthy individuals and routinely interferes with efforts to bond restorations to dental tissues. Our previous studies using tapping-mode atomic force microscopy (TMAFM) have shown that nanophase separation is a general feature of cross-linked polymethacrylates photocured in the presence of water. To explore the relationship between nanophase separation in dentin adhesives and their long-term mechanical properties, we evaluated model adhesives after 3 months of aqueous storage. The degree of contrast in the TMAFM phase image depended on the formulations used, ranging from ‘not observable’ to ‘very strong’. Correspondingly, the mechanical properties of these model adhesives varied from ‘minimal change’ to ‘significant depreciation’. The results support the hypothesis that a high degree of heterogeneity at the nano-scale is associated with poor mechanical durability in these model adhesives.

Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody

The effects of secondary structure on asparagine (N) deamidation in a 22 amino acid sequence (369‐GFYPSDIAVEWESNGQPENNYK‐390) of the crystallizable (Fc) fragment of a human monoclonal antibody (Fc IgG1) were investigated using high‐resolution ultra performance liquid chromatography with tandem mass spectrometry (UPLC/MS). Samples containing either the intact Fc IgG (∼50 kD) (“intact protein”), or corresponding synthetic peptides (“peptide”) were stored in Tris buffer at 37°C and pH 7.5 for up to forty days, then subjected to UPLC/MS analysis with high energy MS1 fragmentation. The peptide deamidated only at N382 to form the isoaspartate (isoD382) and aspartate (D382) products in the ratio of ∼4:1, with a half‐life of ∼3.4 days. The succinimide intermediate (Su382) was also detected; deamidation was not observed for the other two sites (N387 and N388) in peptide samples. The intact protein showed a 30‐fold slower overall deamidation half‐life of ∼108 days to produce the isoD382 and D387 products, together with minor amounts of D382. Surprisingly, the D382 and isoD387 products were not detected in intact protein samples and, as in the peptide samples, deamidation was not detected at N388. The results indicate that higher order structure influences both the rate of N‐deamidation and the product distribution.

Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery in vitro and in vivo release studies

Abstract Films and microspheres were prepared from various esters of hyaluronic acid. A model drug, methylprednisolone, was either physically incorporated into the polymer matrix or chemically bound to the polymer backbone through an ester linkage. In vitro release from films with covalently bound drug was much slower ( t 50% = 71 h) than that for physically dispersed drug ( t 50% = 2.5−17 h). Methylprednisolone concentrations in the tear fluid of New Zealand rabbits were measured after ocular application of drug (approx. 420 μg) in different dosage forms. When methylprenisolone was physically dispersed in the polymer matrix, in vivo drug release from matrices was slower than that observed in vitro. Compared with a suspension control, peak methylprednisolone concentrations in tear fluid were 9–14 times lower after administration of drug in polymer films and AUC 0–8 h values were 4–7 times higher. These results imply that hyaluronic acid ester preparations can increase the residence time of methylprednisolone in the tear fluid of rabbits.

Comparison of LC and LC/MS Methods for Quantifying N-Glycosylation in Recombinant IgGs

High-performance liquid chromatography (LC) and liquid chromatography/electrospray ionization time-of-flight mass spectrometry (LC/ESI-MS) methods with various sample preparation schemes were compared for their ability to identify and quantify glycoforms in two different production lots of a recombinant monoclonal IgG1 antibody. IgG1s contain a conserved N-glycosylation site in the fragment crystallizable (Fc) subunit. Six methods were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment (293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC analysis of N-glycans cleaved from the IgG using PNGase F. The results suggest that MS quantitation based on the analysis of Fc/2 (4) is accurate and gives results that are comparable to normal phase HPLC analysis of N-glycans (6).